


Applicants: Jeremy Green et al.
Application No.: 10/808,678

THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1-46. (Canceled)

47. (Previously presented) A pharmaceutical composition comprising a compound of formula I:



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein:

R¹ is Ar¹;

R² is hydrogen;

T is CH;

A¹ is C-halogen, C-CN, or C-R;

each of A² and A³ is, independently, CR⁴;

R⁴ is selected from halogen, NO₂, CN, -(L)_mR, -(L)_mAr¹, or -(L)_mCy¹; or


two R⁴ groups on adjacent atoms are taken together to form an optionally substituted 5-7 membered partially unsaturated or fully unsaturated ring having 0-3 heteroatoms independently selected from oxygen, sulfur, or nitrogen, wherein each ring formed by two R⁴ groups on adjacent atoms taken together is optionally substituted with up to 4 occurrences of Z-R^X;

Applicants: Jeremy Green et al.
 Application No.: 10/808,678


L is a C₁₋₆ alkylidene chain wherein one methylene unit of L is optionally replaced by
 -O-, -N(R)-, -N(R)C(O)-, -C(O)-, -C(O)N(R)-, -SO₂N(R)-, or -N(R)SO₂-;

m is 0 or 1;

Ar¹ is



Cy¹ is selected from



Ar¹ and Cy¹ are each optionally substituted with up to 5 occurrences of Z-R^X; wherein
 each occurrence of Z is independently a bond or a C₁₋₆ alkylidene chain, wherein up to
 two non-adjacent methylene units of Z are optionally replaced by -S-, -O-, -N(R)-,
 -N(R)C(O)-, -C(O)N(R)-, -SO₂N(R)-, or -N(R)SO₂-;

each occurrence of R^X is independently selected from -R', halogen, NO₂, CN, -OR',
 -SR', or -N(R')₂,

each occurrence of R is independently hydrogen or a C₁₋₆ aliphatic group; and

each occurrence of R' is independently hydrogen, a C₁₋₆ aliphatic group, a C₆₋₁₀ aryl ring,
 a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring
 atoms; or


Applicants: Jeremy Green et al.
Application No.: 10/808,678

R and R' or two occurrences of either R or R' are taken together with the atoms to which they are bound to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

two occurrences of either R' or R on the same nitrogen are taken together with the nitrogen atom to which they are bound to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

48-49. (Canceled)

50. (Currently amended) A method of inhibiting c-MET kinase activity in a biological sample, wherein said biological sample is selected from a cell culture, biopsied material obtained from a mammal, saliva, urine, feces, semen, or tears, or an extract thereof; which method comprises contacting said biological sample with a composition according to claim 47 ~~or a compound of formula I:~~



~~or a pharmaceutically acceptable salt thereof, wherein:~~

~~R¹ is Ar¹;~~

~~R² is hydrogen;~~

~~T is CH;~~

~~A¹ is C-halogen, C-CN, or C-R;~~


~~each of A² and A³ is, independently, CR⁴;~~

Applicants: Jeremy Green et al.
 Application No.: 10/808,678


R^4 is selected from halogen, NO_2 , CN , $(L)_m R$, $(L)_m Ar^1$, or $(L)_m Cy^1$; or
 two R^4 groups on adjacent atoms are taken together to form an optionally substituted 5-7
 membered partially unsaturated or fully unsaturated ring having 0-3 heteroatoms
 independently selected from oxygen, sulfur, or nitrogen, wherein each ring formed by
 two R^4 groups on adjacent atoms taken together is optionally substituted with up to 4
 occurrences of ZR^x ;

L is a C_{1-6} alkylidene chain wherein one methylene unit of L is optionally replaced by
 $-O-$, $N(R)-$, $N(R)C(O)-$, $C(O)-$, $C(O)N(R)-$, $SO_2N(R)-$, or $N(R)SO_2-$;
 m is 0 or 1;


Ar^1 is selected from



Applicants: Jeremy Green et al.
 Application No.: 10/808,678



Cy^+ is selected from



wherein;

Ar^+ and Cy^+ are each optionally substituted with up to 5 occurrences of $Z-R^X$; wherein each occurrence of Z is independently a bond or a C_{1-6} alkylidene chain, wherein up to two non-adjacent methylene units of Z are optionally replaced by $-S-$, $-O-$, $-N(R)-$, $-N(R)C(O)-$, $-C(O)N(R)-$, $-SO_2N(R)-$, or $-N(R)SO_2-$;

each occurrence of R^X is independently selected from R' , halogen, NO_2 , CN , OR' , SR' , or $N(R')_2$;

each occurrence of R is independently hydrogen or a C_{1-6} aliphatic group; and

each occurrence of R' is independently hydrogen, a C_{1-6} aliphatic group, a C_{6-10} aryl ring, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms; or

Applicants: Jeremy Green et al.
Application No.: 10/808,678

~~R and R' or two occurrences of either R or R' are taken together with the atoms to which they are bound to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or~~
~~two occurrences of either R' or R on the same nitrogen are taken together with the nitrogen atom to which they are bound to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.~~

51-80. (Canceled)

81. (Previously presented) The composition according to claim 47, wherein A^2 is CR^4 and R^4 is halogen, CN, $-(L)_mR$, $-(L)_mAr^1$, or $-(L)_mCy^1$.


82. (Canceled)

83. (Previously presented) The composition according to claim 81, wherein A^2 is CR^4 and R^4 is halogen or R.

84. (Previously presented) The composition according to claim 81, wherein A^2 is CR^4 and R^4 is $-(L)_mR$, wherein L is -O- or -N(R)-.


85. (Previously presented) The composition according to claim 81, wherein A^2 is CR^4 , R^4 is $-(L)_mCy^1$, m is 0 and Cy^1 is

Applicants: Jeremy Green et al.
 Application No.: 10/808,678




86. (Canceled)

87. (Previously presented) The composition according to claim 81, wherein A^2 is CR^4 , R^4 is $-(L)_mR$, and compounds have the formula **IE-1**:



IE-1.


88. (Previously presented) The composition according to claim 81, wherein A^2 is CR^4 , R^4 is $-(L)_mAr^1$, and compounds have the formula **IE-2**:



IE-2 .

Applicants: Jeremy Green et al.
 Application No.: 10/808,678

89. (Previously presented) The composition according to claim 81, wherein A^2 is CR^4 , R^4 is $-(L)_mCy^1$, and compounds have the formula **IE-3**:



IE-3 .


90. (Previously presented) The composition according to claim 47, wherein A^3 is CR^4 and R^4 is halogen, CN, $-(L)_mR$, $-(L)_mAr^1$, or $-(L)_mCy^1$.

91. (Canceled)

92. (Previously presented) The composition according to claim 90, wherein A^3 is CR^4 and R^4 is halogen or R.

93. (Previously presented) The composition according to claim 90, wherein A^3 is CR^4 and R^4 is $-(L)_mR$, wherein L is $-O-$ or $-N(R)-$.


94. (Previously presented) The composition according to claim 90, A^3 is CR^4 , R^4 is $-(L)_mCy^1$, m is 0 and Cy^1 is



Applicants: Jeremy Green et al.
Application No.: 10/808,678


95. (Canceled)

96. (Previously presented) The composition according to claim 90, wherein A^3 is CR^4 , R^4 is $-(L)_mR$, and compounds have the formula **IF-1**:



IF-1 .


97. (Previously presented) The composition according to claim 90, wherein A^3 is CR^4 , R^4 is $-(L)_mAr^1$, and compounds have the formula **IF-2**:



IF-2 .

98. (Previously presented) The composition according to claim 90, wherein A^3 is CR^4 , R^4 is $-(L)_mCy^1$, and compounds have the formula **IF-3**:


Applicants: Jeremy Green et al.
 Application No.: 10/808,678




IF-3 .

99-100. (Canceled)


101. (Currently amended) The composition according to claim 47, selected from one of the following compounds:




I-1,




I-2,




I-3,



I-4,




I-11,




I-12,


Applicants: Jeremy Green et al.
Application No.: 10/808,678




I-13,




I-14,




I-15,




I-17,




I-18,




I-19,




I-20,




I-21,



I-22,




I-23,




I-24,


Applicants: Jeremy Green et al.
Application No.: 10/808,678




I-25,




I-26,




I-27,




I-28,



I-29,




I-31,




I-32,


Applicants: Jeremy Green et al.
Application No.: 10/808,678




I-33,




I-34,



I-35,



I-36,



or **I-37** .